Italia markets closed

Codexis, Inc. (CDXS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,8800+0,0100 (+0,26%)
Alla chiusura: 04:00PM EDT
3,9800 +0,10 (+2,58%)
Dopo ore: 07:59PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente3,8700
Denaro3,7500 x 1200
Lettera3,8900 x 1400
Min-Max giorno3,7950 - 3,9500
Intervallo di 52 settimane3,7900 - 22,2200
Media Volume654.721
Beta (5 anni mensile)1,63
Rapporto PE (ttm)N/D
EPS (ttm)-0,5100
Prossima data utili03 mag 2023 - 08 mag 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A12,88
  • GlobeNewswire

    Codexis Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis’s Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 43,403 shares of Codexis’ common stock and (ii) restricted stock units (RSUs) for 9,723 shares of Codexis common stock as induceme

  • GlobeNewswire

    Codexis to Participate in Cowen 43rd Annual Health Care Conference

    REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in Boston, Massachusetts. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, will participate in a panel discussion titled, “SynBio & AI Driven Drug Discovery,” taking place on Mo

  • GlobeNewswire

    Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results

    Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational New Drug Applications Cash Runway Through End of 2024 Funds Important Upcoming Milestones Company Provides 2023 Revenue Guidance REDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a busine